Ticker brief
KYMR
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
9
authors 14d
6
crowd 14d
-1.3σ
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Options inteloptions-surface reads · latest available day per source
| metric | reading | context |
|---|---|---|
| IV — ATM 30d | 57% | HV n/a |
| Skew — 25Δ RR 30d | -0.125 | 25Δ call IV − put IV |
| OI alarm | quiet | last alarm 2026-06-29 (z=4.1) |
Sentiment — last 14 days
daily mean sentiment, 2026-10-02 → 2026-10-15 · now -0.30 (−1 bearish … +1 bullish)
Who spoke6
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @semodough | C | -1.06 | 3 | -0.03 |
| @Biotech2k1 | A | +1.11 | 2 | -0.12 |
| @Quantumup1 | C | +0.10 | 1 | +0.40 |
| @TheNewMoney_app | C | · | 1 | -0.40 |
| @cnfinancewatch | B | -1.23 | 1 | +0.40 |
| @bioinvestor24 | A | -0.87 | 1 | -0.30 |
Recent signals9of 9 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-15 | @bioinvestor24 | -0.30 | Questions the convenience thesis for oral drugs and favors AbbVie's quarterly injection strategy over Kymera. | · | tweet ↗ |
| 2026-10-14 | @semodough | +0.10 | Relays dermatologist efficacy and monitoring thresholds for oral treatments versus Dupixent. | · | tweet ↗ |
| 2026-10-13 | @Biotech2k1 | -0.65 | Labels the named biotech stocks as bubble names and excludes them from bargains. | · | tweet ↗ |
| 2026-10-12 | @cnfinancewatch | +0.40 | Lists six recent sell-side price-target increases with prior and new targets. | · | tweet ↗ |
| 2026-10-09 | @semodough | -0.55 | Questions KYMR's valuation at 10x CRVS, 7x NKTR and 1.5x ABVX. | · | tweet ↗ |
| 2026-10-09 | @semodough | +0.35 | Lists four upcoming KYMR clinical catalysts from late October 2026 through late 2027. | · | tweet ↗ |
| 2026-10-07 | @TheNewMoney_app | -0.40 | Reports a $366,460 purchase of KYMR 80 puts expiring December 17, 2027. | · | tweet ↗ |
| 2026-10-05 | @Quantumup1 | +0.40 | Citi raised KYMR's target to $150 from $135 while maintaining Buy. | · | tweet ↗ |
| 2026-10-02 | @Biotech2k1 | +0.40 | Names six biotech companies repeatedly selected for potential 20-year returns. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.